BALTIMORE, MD — Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Maggie Rougier-Chapman as Senior Vice President, Head of Marketing and Commercial Strategy. In this critical role, Ms. Rougier-Chapman will lead the company’s marketing and commercial planning efforts to drive global growth and patient impact by creating broader awareness and accelerating customer adoption of the PGDx elio™ product line.
“I am delighted to welcome Maggie Rougier-Chapman, an accomplished executive in the field of genomics and precision diagnostics, to the PGDx management team,” said Megan Bailey, Chief Executive Officer. “Maggie brings over 15 years of success driving business growth for both large multinational and rapidly scaling companies through commercialization of genomic solutions for clinical and research use, and we look forward to the significant impact of her contributions to advancing our mission.”
Most recently, Ms. Rougier-Chapman served as Head, Oncology Product Management & Strategy at Invitae, having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President, Commercial Operations. In this role, she prepared ArcherDX for a successful exit and integration by reshaping the company’s product management, marketing & sales operations to support revenue growth, companion diagnostic (CDx) program expansions and global product launches of NGS-based in vitro diagnostics for therapy selection and monitoring.
Ms. Rougier-Chapman is a strategic leader with deep domain expertise spanning the diagnostics and genomics sectors. Previously, she was Vice President, Global Marketing, at Bionano Genomics, where she led marketing, product management, and branding for the company’s optical genome mapping technology. Prior to Bionano, Ms. Rougier-Chapman spent several years in key management roles within the sales and marketing function of Agilent Technologies’ Diagnostics and Genomics Division, as well as various commercial roles at Advanced Cell Diagnostics, Cogenics, Incyte Genomics, and Stratagene. Ms. Rougier-Chapman holds an M.S. in Molecular Cancer Biology and a B.S. in Biology with a certificate in Genetics from Duke University.
“I am delighted to join PGDx, and look forward to building a world-class marketing organization,” said Ms. Rougier-Chapman. “I am inspired by PGDx’s dedication to advance the field of precision oncology by improving patient access to biomarker-guided clinical decision making with a portfolio of comprehensive, standardized tissue & liquid biopsy assays that enable rapid, local testing where patients with cancer receive their care.”
PGDx currently offers three pan-cancer NGS kitted solutions – elio™ tissue complete, an FDA cleared kit, elio™ plasma complete, a comprehensive liquid biopsy solution, and elio™ plasma resolve, which has received FDA breakthrough device designation – that provide researchers and clinicians with the ability to identify biomarkers and profile tumors through advanced genomic sequencing within their own hospital systems and laboratories.
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. PGDx’s elio™ Platform has enabled the development of standardized tissue-based and liquid biopsy nextgeneration sequencing (NGS) kits for laboratories worldwide, featuring automated bioinformatics that ensures consistent results and quality of testing. By automating the data analysis process, PGDx is enabling the scalability of precision medicine with a fast, reliable, and accurate diagnostics platform.
For additional information, visit www.pgdx.com.
View source version on businesswire.com: